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ABSTRACT
Objective: Hyperthermia therapy (HT), heating tumors to 40–45 C, is a known radiotherapy (RT) and
chemotherapy sensitizer. The additional benefit of HT to RT for recurrent breast cancer has been pro-
ven in multiple randomized trials. However, published outcome after RTþHT varies widely. We per-
formed a systematic review to investigate whether there is a relationship between achieved HT dose
and clinical outcome and thermal toxicity for patients with recurrent breast cancer treated
with RTþHT.
Method: Four databases, EMBASE, PubMed, Cochrane library and clinicaltrials.gov, were searched with
the terms breast, radiotherapy, hyperthermia therapy and their synonyms. Final search was performed
on 3 April 2019. Twenty-two articles were included in the systematic review, reporting on 2330
patients with breast cancer treated with RTþHT.
Results: Thirty-two HT parameters were tested for a relationship with clinical outcome. In studies
reporting a relationship, the relationship was significant for complete response in 10/15 studies, in 10/
13 studies for duration of local control, in 2/2 studies for overall survival and in 7/11 studies for ther-
mal toxicity. Patients who received high thermal dose had on average 34% (range 27%–53%) more
complete responses than patients who received low thermal dose. Patients who achieved higher HT
parameters had increased odds/probability on improved clinical outcome and on thermal toxicity.
Conclusion: Temperature and thermal dose during HT had significant influence on complete response,
duration of local control, overall survival and thermal toxicity of patients with recurrent breast cancer
treated with RTþHT. Higher temperature and thermal dose improved outcome, while higher max-
imum temperature increased incidence of thermal toxicity.
ARTICLE HISTORY
Received 29 July 2019
Revised 30 August 2019
Accepted 30 August 2019
KEYWORDS
Thermal dose; clinical trials-
superficial; breast cancer;
clinical outcome; toxicity
Introduction
Hyperthermia therapy (HT), increasing the tumor temperature
to 40–45 C, is a known radiotherapy (RT) and chemotherapy
sensitizer. The additional benefit of HT to RT and chemother-
apy has been proven in randomized trials for melanoma, sar-
coma, recurrent breast cancer, cervical cancer and other
tumor types [1–5]. A recent systematic review showed the
additional value of HT to RT for patients with locoregional
recurrent breast cancer [6]. Complete response rate increased
from 38.1% for patients treated with RT to 60.2% for patients
treated with RTþHT, respectively. The complete response of
RTþHT varied widely throughout the included studies; range
33.3%–95.0% [7,8]. An important factor contributing to this
wide variation was hypothesized to be the variability in HT
delivery, that is the HT technique, sequencing of RT and HT,
duration of HT and temperature and thermal dose achieved
during HT treatment [6].
Techniques used in the past and in the present vary in
effective field size and penetration depth depending on the
design and used frequency of the technique [9], resulting in
variations in temperature and thermal dose achieved during
HT treatment. Furthermore, the amount of radiosensitization
by HT is strongly dependent on the sequence and time-inter-
val between RT and HT, where the effect is largest when HT
and RT are given simultaneously [10,11]. This maximum
radiosensitization for simultaneous application is observed
for both tumor and normal tissue.
A thermal dose–effect relationship for HT has been
reported in the literature, both in pre-clinical and clinical
studies. In vitro studies show that there is an increase in cell
death when tumor cells are heated longer or to a higher
temperature [12–14]. Several clinical studies underline the
importance of duration of HT and temperature and thermal
dose achieved during HT treatment [15,16]. The effect of HT
increases with a longer heating time, but during and after
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exposure to heating the onset of thermotolerance is induced,
which results in a temporarily reduced sensitivity to heating
[17,18]. This reduced effectiveness of HT is a transient effect
and persists for several days [18]. Therefore, clinical HT treat-
ments are limited to 1–1.5 h, once or twice weekly. As a result
of the observed thermal dose-effect relationship, HT treat-
ments are usually quantified by calculating a ‘thermal isoeffec-
tive dose’, which captures both temperature and time. The
most commonly used thermal isoeffective dose is the number
of equivalent minutes at 43 C (CEM43) [19,20]. Other parame-
ters representing minimum or median tumor temperature lev-
els achieved during HT, include T90, T50, and TRISE [21–23].
We performed a systematic review to determine whether
the large variation in outcome observed in clinical studies for
patients with recurrent breast cancer treated with RTþHT
can be explained by variation in achieved temperatures and
thermal dose during HT treatment.
Methods
The systematic review was conducted following the PRISMA
guidelines [24]. Four databases were searched from inception
to 3 April 2019: EMBASE, PubMed, Cochrane library and clini-
caltrials.gov. An initial search was performed in PubMed, and
relevant articles were found by citation tracking. The syno-
nyms for breast, hyperthermia therapy and radiotherapy
reported in those articles were used as entrance parameters in
the final search. For each database an individual search was
performed. In PubMed the following search was executed:
(‘Breast’[Mesh] or breast[tw] or mamma[tw] or mammary[tw])
AND (‘Hyperthermia, Induced’[Mesh] or hyperthermia[tw] or
heat[tw] or thermotherapy[tw] or thermoradiotherapy[tw])
AND (‘Combined Modality Therapy’[Mesh] or ‘Radiotherapy’
[Mesh] or radio[tw] or radiation[tw] or irradiation[tw] or reirra-
diation[tw] or re-irradiation[tw] or radiotherapy[tw] or thermor-
adiotherapy[tw]). In clinicaltrials.gov studies for breast cancer
and hyperthermia were searched, while a filter for the inter-
vention type, that is not drugs, was applied. The search was
not limited to any date, both articles and conference proceed-
ings were allowed, a filter for English articles and human stud-
ies was applied. When warranted we contacted study authors
to identify additional studies.
Inclusion criteria
Single-arm, double-arm, retrospective and prospective stud-
ies (randomized and non-randomized) fulfilling the following
criteria were included: Patients with recurrent breast cancer
treated with external beam RT and local HT.
Study selection
After exclusion of duplicates, articles were screened accord-
ing to their titles and abstracts (Figure 1). Articles were
excluded when:
 Articles were not clinical studies.
 Patients received concurrent chemotherapy or drugs.
 The endpoint of the study was not outcome.
 The relationship between thermal dose parameters and
outcome was not analyzed.
 Less than ten patients or lesions with breast cancer
treated with RTþHT were reported.
 Articles were updated in a later publication by the
same author(s).
 Mixed patient groups were reported and the outcomes of
breast cancer patients were not analyzed separately.
Articles from the same authors describing the tempera-
ture analysis of the HT treatment in more detail were taken
into account.
Data extraction and quality assessment
The primary endpoints of interest were the relationships
between temperature and/or thermal dose during HT with
clinical outcome: complete response (CR), duration of local
control (LC), overall survival (OS) as well as thermal toxicity
(i.e., acute blisters). Details of the (pre) treatment patient
characteristics and present treatment parameters were inves-
tigated, as well as clinical outcome.
The relationships between thermal dose parameters and
CR, LC, OS, and thermal toxicity were tested in univariate
and multivariate analysis. A p value<.05 was considered sig-
nificant, p between .05 and .1 a trend and for p .1 we con-
cluded that there was no relationship. Furthermore, we
registered whether a parameter was mentioned by the
authors but not reported as related to outcome, which we
interpreted as that the analysis was either not performed or
not reported. This selective reporting within studies is a pos-
sible publication bias. An overview of the relationships of
thermal dose parameters to CR, LC, OS, and thermal toxicity
is presented in a graph. In this graph, the thermal dose
parameters are grouped in categories as either high-end
temperature (e.g., maximum temperature, T10, T20), mean
temperature (e.g., mean and median temperature), and low-
end temperature (e.g., T90 and minimum temperature) and
as either high-end dose (e.g., maximum CEM43, time >
43 C), mean dose (e.g., CEM43T50) and low-end dose (e.g.,
CEM43T90, minimum CEM43, time < 40 C). The number of
HT treatments is considered as a separate category. T10, T20,
and T90 are the 90th, 80th, and 10th percentile of all tem-
perature measurements, respectively. For each category, a
study is taken into account once. We selected the parameter
that had the strongest relationship with the out-
come variables.
The odds ratio (OR), risk ratio (RR) and risk difference (RD)
was calculated for studies which reported the clinical out-
come measures for patients grouped based on the value of
their thermal dose parameters during HT treatment. The OR
and RR are expressed as the logarithmic average with the
95% confidence interval (CI). The RD is expressed as the aver-
age with the 95% CI. When one of the events was zero, for
example, patients with a low thermal dose had no CR, we
first added 0.5 to all categories and then calculated the OR,
RR, or RD (Haldane-Anscombe correction) [25]. The statistical
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analysis was performed in R (version 3.5.1) with package
‘metafor’ (version 2.0-0). No meta-analysis was performed
due to the strong variation in definitions of thermal
dose parameters.
The study selection and risk of bias assessment (QUIPS)
[26] were performed by author AB. Data extraction was done
by authors JZ and AB.
Results
A total of 1249 articles were identified through the search and
were screened (Figure 1). Twenty-five studies described in 22
articles were included in the systematic review, reporting a total
of 2330 patients with breast cancer. Two additional articles pre-
senting a detailed temperature analysis of the studies presented
by Vernon et al. [4] were taken into account [15,27].
Patient and treatment characteristics
In total 1749 patients with macroscopic disease (77.0%) and
563 patients with microscopic disease (23.0%) were reported.
Most patients were treated for recurrent disease (n¼ 2304,
98.9%), while 26 patients (1.1%) were treated for primary dis-
ease. Patients received RTþHT for the breast (n¼ 256), chest
wall (n¼ 1861), and lymph nodes (n¼ 181) (Table 1).
Most patients had previously received extensive treatment
on the areas treated with RTþHT. RT was previously given
with a median dose of 50.0 Gy (range 32–65) to 2007
patients (86.1%). At least 1773 patients (76.1%) underwent
surgery in the currently treated area, 1319 patients (56.6%)
received prior chemotherapy and 971 patients (41.7%)
received prior hormonal therapy.
During RTþHT treatment, patients were treated with a
median RT dose of 36Gy (range 29–56) and either microwave
HT (n¼ 2155), radiofrequency HT (n¼ 135), interstitial HT
(n¼ 31), ultrasound HT (n¼ 26), capacitive HT (n¼ 24) or with
a mix of HT devices with different frequencies (n¼ 8)
(Table 1). HT treatments had an average duration of
52.8±10.4min (SD). HT was given mostly once or twice per
week and in one study every 2 weeks. Patients received five
HT treatments (median, range 2–10). In one study RT was
given after HT (as soon as possible), while in 19 studies HT
was given after RT. The time interval between RT and HT var-
ied from <30min (9 studies), <45min (3 studies), <60min
(8 studies), 80min (1 study) to >90min (1 study). Three studies
did not report the time interval between RT and HT (Table 1).
Temperature and thermal dose measurement
Temperature during HT was measured invasively in all 25
studies, but not in all patients. The type of thermometry
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equipment and the number of temperature sensors were
poorly reported (Table 1). A total of 32 thermal dose parame-
ters were tested for a relationship with outcome.
Thermal dose parameters were derived from superficial
temperature sensors, invasive temperature sensors or from a
combination. Thermal dose parameters measured superfi-
cially showed no relationship with CR, LC, and OS, but did
show a relationship with thermal toxicity. Thermal dose
parameters derived from invasive measurements correlated
with all outcome measures, that is CR, LC, OS, and thermal
toxicity (Table 2, supplementary materials).
Clinical outcome
The log OR, log RR, and RD are above zero for all clinical out-
come measures in every study (Figure 2(A–C)). Thus, patients
achieving a higher thermal dose parameter during HT treat-
ment had an increased odds/probability of CR, longer dur-
ation of LC, longer OS and more thermal toxicity. An
overview of all reported thermal dose parameters in the
included studies with their respective statistical relationships
to the outcome measures and their respective thermal dose
category is available as supplementary materials.
Complete response
Eight studies reported a significant univariate relationship
between CR and thermal dose [28–31] or temperature
[32,33,39,42] (Figure 3 and Table 1). Four studies
[29,34,35,39] reported a trend (p< .1) between temperature
and CR, while two studies did not find any relationship
between CR and thermal dose parameters [43,44].
Multiple studies showed a significant relationship between
the achieved thermal dose invasively (CEM42.5, CEM43, time
> 42.5 C, time > 43 C) and CR (Figure 4). Patients who
received a high thermal dose had on average 34% (range
27%–53%) more CR than patients who received a low ther-
mal dose [4,15,28–34].
Several studies investigated the relationship between tem-
perature and CR. Gabriele et al. [32] found that the CR rate
was correlated with the average maximum (skinþ invasive)
temperature during HT treatment (42 C 76.5% CR vs.
<42 C 30% CR), while there was no correlation with average
temperature or minimum temperature (Figure 3). Similarly,
van der Zee et al. [42] showed that the CR rate increased
with a higher maximum temperature in normal tissue
(p< .04), while neither the maximum temperature in tumor
tissue (p¼ .29) nor the T90 for normal (p¼ .62) or tumor tis-
sue (p¼ .30) showed an association with CR. Lindholm et al.
[39] found that none of the investigated thermal factors pre-
dicted CR. However, for the subgroup treated with 915MHz
(n¼ 55/59), the minimum temperature in the HT session with
the highest temperatures, was predictive for CR (p¼ .02).
Seegenschmiedt et al. [33] also found a significant relation-
ship between the mean minimum temperature, the min-
imum temperature of the first session and of the best
session and CR. A minimum invasive temperature above
41 C resulted in a significantly better CR. Sannazzari et al.
[34] also found that higher minimum temperatures increased
the CR rate (Figure 2).
Both studies that did an in-depth temperature analysis on
the trials reported in Vernon et al. [4], found statistically sig-
nificant multivariate relationships with minimum thermal
dose [15,27], after adjusting for maximum tumor depth and
RT regimen (radical or palliative RT) [27] and after adjusting
for systemic disease at entry and tumor depth [15].
Local control
In univariate analysis, duration of LC was significantly corre-
lated with minimum temperature [33,35,36], T90 [35,40,42]
and average temperature [40]. Furthermore, Kapp et al. [45]
found that the average percentage of temperatures 40 C
was significantly correlated with duration of LC (p< .05;
Figure 2). Van der Zee et al. [42] also found that duration of
LC was improved by a higher maximum normal tissue tem-
perature (p¼ .02; Figure 3). Three studies found no relation-
ship (Table 1).
Kapp et al. [35] found that macroscopic tumor lesions
that had an average minimum temperature 40.75 C or
with <20% temperatures <41 C had longer LC. In patients
with microscopic disease, Kapp et al. [36], confirmed that
patients achieving an average minimum temperature
39.7 C or 96% temperatures 40 C resulted in signifi-
cantly longer LC. Seegenschmiedt et al. [33] found a signifi-
cant relationship between LC and the mean minimum
temperature, the minimum temperature of the first session
and of the best session. Where an invasive minimum tem-
perature above 41 C resulted in significantly better duration
of LC [33]. Lee et al. [37] found that patients who achieved
temperatures >43 C for a longer duration showed improved
duration of LC [37] (Figure 2).
Eight studies investigated the relationship between the
number of HT treatments and LC. Four found a significant
relationship [36,37,41,46] and two a trend [38,39]. Kapp et al.,
[36] found that 2 HT treatments improved duration of LC
compared to one treatment in total. Hehr et al. [46] found
that >7 HT sessions improved duration of LC. Lee et al. [37]
treated patients with a median of eight treatments, where
more treatments were better, which remained significant in
multivariate analysis. Arcangeli et al. [38] treated one patient
with 40 lesions, where a lesion was either treated with one
or four HT treatments. When a lesion received four HT treat-
ments there was less tumor regrowth and longer freedom
from local progression (Figure 2).
In multivariate analysis, several thermal dose parameters
remained significant for a relationship with duration of LC:
 The minimum thermal dose after adjusting for systemic
disease at entry [4,15].
 The average temperature after adjusting for lesion size
and time interval between diagnosis primary tumor and
present treatment [39].
 The percentage temperature 40 C after adjusting for
estrogen receptor status, initial T-stage, time interval
between initial breast cancer to first failure, age at HT
and concurrent RT [36].
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 The number of HT treatments and 10min >43 after
adjusting for initial specific absorption rate (SAR), current
RT dose, tumor volume, and tumor thickness [47].
Overall survival
Both studies investigating the relationship between thermal
dose parameters and OS found a positive relationship. Most
relevant thermal dose parameters correlating with sur-
vival are:
 The time >42.5 C. Refaat et al. [31] reported that when
patients were treated with more than 200min above
42.5 C, patients had better OS. This remained significant
in multivariate analysis after adjusting for microscopic dis-
ease, RT dose and mastectomy.
 CEM43T100. The DHG, ESHO, and PMH trials [4,15] found
in multivariate analyses that OS at 18 months after treat-
ment was significantly better for patients who received
more than 6min CEM43T100 compared to patients who
received less than 6minutes CEM43T100, 57% versus
22%, respectively, after adjusting for systemic disease at
entry, age, and tumor area (Figure 2).
Thermal toxicity
Overall, seven studies report a relationship between toxicity
and maximum temperature [33,36,39–41,48,49], of which two
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Figure 3. The number of studies where a high-end, mean, or low-end thermal parameter (T), thermal dose parameter (TD) or number of hyperthermia treatments
(#HT tr), is reported in relation to complete response, duration of local control, overall survival and thermal toxicity. The univariate or multivariate relationship of
the thermal dose parameters with one of the outcome measures is labeled as either a significant relationship (p< .05) a trend (p values between .05 and .1), no
relationship (p .1) or as not done or not reported. The labels inside the bars represent the number of studies.
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studies also report a relationship with thermal dose [41,48].
Furthermore, Lindholm et al. [39] found that two HT treat-
ments per week gave more severe skin reactions than one
treatment per week. Linthorst et al. [41] found that the aver-
age temperature on the skin had a relationship with thermal
toxicity. While four studies report no relationship (Figure 3
and Table 1) [28,30,42,44].
Several studies showed a relationship between the
recorded maximum temperature on the skin and thermal
toxicity (Figure 2). Engin et al. [49] found that patients with-
out a skin reaction had a maximum temperature on the skin
of 42.1 ± 0.5 C (mean± SD), while patients with thermal blis-
ters had a maximum temperature of 43.7 ± 0.2 C (p< .01).
Seegenschmiedt et al. [33] found that thermal adverse events
(superficial blisters and deep burns) were significantly corre-
lated with maximum temperatures of more than 45 C
(p< .01). Lindholm et al. [39] found that one of the prognos-
tic factors for blisters was the highest average maximum skin
temperature during a given HT treatment (p¼ .03). The cor-
relation between normal tissue damage and maximum skin
temperature was even stronger (p¼ .01) when only tumors
treated with 915MHz were considered (n¼ 55/59). Linthorst
et al. [41] found that invasively measured thermal parameters
had no influence on thermal toxicity, whereas the incidence
of grade 2 and 3 burns clearly increased with a higher max-
imum skin temperature. Patients with a maximum skin tem-
perature <43 C had a grade 2 or 3 burn incidence of 15%,
while incidence was 32% in patients with a maximum skin
temperature >43 C (p¼ .006). In 2015, Linthorst et al. [40]
again showed that the incidence of grade 2 and 3 skin burns
increased with a higher maximum skin temperature; 13%
incidence when the maximum skin temperature was <43 C
and 28% when >43 C (p¼ .003), see Figure 5. Likewise,
Bakker et al. [48] found in multivariate analysis a significant
relationship between the maximum temperature on the skin
and the occurrence of thermal skin damage adjusted for
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Figure 5. The incidence of thermal toxicity (blisters) increases with a higher maximum skin temperature. Data was adapted from Lindholm et al. [39], Linthorst
et al. [41], and Linthorst et al. [40] combined with probability models for thermal toxicity for scar and skin tissue [48].
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patient and tissue type, they derived probability models for
skin toxicity for scar and skin tissue (Figure 5).
Multivariate analysis by Kapp et al. [36] revealed a higher
maximum invasive temperature in fields developing adverse
events (cutaneous and/or subcutaneous induration/fibrosis,
normal tissue burns/ulceration, edema, pain) compared with
fields free of adverse events (45.8 C vs. 45.2 C, respectively;
p¼ .005), after adjusting for HT device, tumor stage and site.
Furthermore they found a correlation for the percentage of
invasive temperature 45 C, after adjusting for HT device,
tumor stage and site.
Three studies [30,42,44] found no correlation between
thermal parameters and adverse events. Although, van der
Zee et al. [42] did find a correlation between the technique
used to deliver HT, for example, 434MHz treatments caused
much less acute damage than 2450MHz treatments
(p¼ .001). They reported that the acute damage for
2450MHz systems was likely due to having no water bolus
cooling. Indeed, when Lindholm et al. [50] added water
bolus cooling to a 2450MHz system, toxicity decreased from
55% to 17%.
Discussion
This systematic review shows that for patients with locore-
gional recurrent breast cancer treated with RTþHT higher
temperature and/or thermal dose during HT improves CR, LC
and OS [4,15,27–33,35–37,39,40,42], while increasing the inci-
dence of thermal toxicity [33,36,39–41,48,49]. It is intriguing to
see that the CR of patients who received RT alone versus
patients who received RTþ low dose HT were comparable;
38.1% [6] versus 36.2% (Figure 4), respectively. Comparable
benefit in CR was found when either RTþHT or RTþ high
dose HT was received; 60.2% [6] versus 66.6% (Figure 4),
respectively. The achieved temperature and thermal dose dur-
ing HT thus at least partly explains the reported variation in
CR after RTþHT in patients with recurrent breast cancer [6].
Optimizing the temperature and thermal dose of HT treat-
ment in patients with locoregional recurrent breast cancer in
reirradiated area is therefore of utmost importance. The
included studies aimed for minimum temperatures between
41 C and 43 C, which were rarely achieved. Whereas the
achieved maximum temperature was frequently higher than
the beforehand specified allowed maximum temperature, which
varied between 43 C and 50 C. This implies a very heteroge-
neous temperature distribution which led to the minimum goal
temperatures and allowed maximum temperatures to vary
widely between institutes. The recently published ESHO guide-
lines for superficial HT quality assurance might help to improve
overall quality assurance practice and reduce variation between
institutes. These guidelines advise to aim for a T90> 40 C and
T50> 41 C to achieve local tumor control, with maximum tem-
peratures of 43–45 C [51]. Furthermore, hyperthermia techni-
ques have improved over the years and more uniform and
adequate heating is presently feasible.
Temperature and thermal dose measurement
Although achieved temperatures and thermal dose of HT
treatment determined treatment quality, these treatment
parameters were often not reported. Six studies concerning
HT and RT in patients with recurrent breast cancer were
excluded from this review because no temperature data
were reported. In the studies that were included, the
reported thermal dose parameters were often not tested for
a relationship with outcome (four studies) or the result of
the tests were not reported (Figure 3).
In total, the values of 27 different thermal dose parame-
ters were presented and 32 parameters were tested for rela-
tionships. These parameters ranged from simple temperature
statistics (minimum, average and maximum temperature,
etc.) to more complex thermal dose parameters (CEM43,
minutes >42.5 C, % temperature >45 C, etc.). Besides that,
there is also an institutional variation in the calculation of
thermal dose parameters. In the rare studies where thermal
dose parameters were reported, the reported parameters var-
ied widely, for example, low-end versus high-end tempera-
tures. Although some correlation is expected because
thermal dose parameters from the high-end, mean and low-
end temperatures are correlated [27, van der Zee, Personal
communications 2019]; comparison of these parameters was
nevertheless difficult.
The measured temperature during HT is vastly dependent
on the type, extent and location of thermometry used; for
example, the number of sensors, type of thermometry equip-
ment [52], location of sensors (e.g., invasive, skin, macroscopic
tumor, scar, and healthy tissue) [48], but also on the use of a
(circulating) water bolus during HT treatment [50]. For
example, it is essential to have a sufficient number of sensors,
because sampling the true temperature distribution during HT
treatment with a small number of temperature sensors may
introduce significant errors in the measured and calculated
thermal dose variables compared to the true underlying tem-
perature distribution [53–57]. Several studies attribute their
inability to find a dose-effect relationship to the low number
of temperature sensors [43,49,58]. Thus, adequate thermom-
etry feedback during treatment and registration of thermal
dose parameters are essential to ensure treatment quality. To
allow comparison of the achieved temperature and thermal
dose between different institutes, an uniform registration, cal-
culation and reporting of thermal dose parameters is required.
Abovementioned arguments were a leading factor in scor-
ing a moderate to high risk of bias in one of the domains of
the QUIPS tool; i.e. the prognostic factor measurement. Only
three out of the 22 included studies had a low risk of bias in
this respective domain (Table 1).
Relationship of thermal dose parameters with outcome
An association between treatment outcome and thermal
dose parameters was not found in all studies. This is not sur-
prising, since most of the included studies were not
designed to investigate the presence of a HT dose-response
effect. Studies aimed at giving a uniform thermal dose
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which, if successful, will result in little variation in HT param-
eters, and thus a relationship of a HT parameter with out-
come is more difficult to prove. Nevertheless, most included
studies (22/25) showed enough variation in several of the
thermal dose parameters to find significant positive relation-
ships with outcome in both univariate and multivariate ana-
lysis. Three studies [43,44,59] did not find any relationship
between thermal dose parameters and CR, LC, and OS. Both
studies of Oldenborg et al. [44,59] only investigated parame-
ters derived from the skin, while Li et al. [43] used a low
number of invasive temperature sensors. Furthermore, uni-
variate analysis does not take into account other patient-,
tumor-, and treatment related parameters, which also con-
tribute to the final outcome of RTþHT. In this systematic
review, only ten studies have performed multivariate analysis
to adjust for patient- tumor-, and treatment related parame-
ters [15,27,31,35–37,39–42,48]. Of these studies, in seven of
the 37 multivariate analyses performed for CR, LC and OS,
the addition of a thermal dose parameter improved the
model. To clarify the need for multivariate analysis, for
example Hehr et al. [46] found that more HT treatments
yielded better duration of LC, but those patients probably
received more RT treatments and thus a higher RT dose
(range 30–68Gy). The RT dose is known to influence treat-
ment outcome in cancer patients. Patients with primary
breast cancer treated with a high RT dose benefit less from
the addition of HT than patients treated with a lower dose
palliative RT scheme [4,16]. Performing a multivariate analysis
to investigate the relationship of outcome with thermal dose
parameters is thus essential to establish a reliable correlation.
Not performing a multivariate analysis yields a high risk of
bias in this situation.
Several studies find a relationship between the number of
HT treatments and duration of LC. However, two randomized
studies investigating the number of HT treatments found no
difference between groups. In a prospective randomized
study, comparing once versus twice weekly HT applications
in 127 patients with chest wall recurrences of breast cancer,
no difference was found in CR and duration of LC [60]
(patients also reported in [33]). Similarly, Kapp et al. [61]
compared two versus six HT treatments in 70 patients with
superficially located tumors and found no difference in CR
and duration of LC. For both studies, the RT dose was similar
between groups.
In general, the addition of HT to RT is well tolerated and
adds no significant late toxicity in patients treated with
RTþHT, although more blistering occurs during RTþHT
compared to RT alone [4]. This acute thermal toxicity is
caused by higher maximum temperatures [33,36,39–41,48,49]
and thermal dose [41,48] on the skin during HT treatment. In
untreated healthy skin, a higher thermal dose on the skin
also increases blistering [62,63].
As shown in Table 2, thermal dose variables derived super-
ficially were predictive for thermal toxicity, while thermal dose
variables derived from invasive temperature sensors were pre-
dictive for both CR, LC, OS, and thermal toxicity. Surface tem-
perature measurements during HT reflect an average of the
water bolus and the true surface temperature. Nevertheless,
the true surface temperature might indeed have a significant
relationship with outcome. Therefore, it is important to meas-
ure both invasive and superficial temperatures during treat-
ment and to report them separately.
Other HT parameters that are related to outcome are the
SAR coverage [37], type of HT device [37,42] and frequency
[36,42]. These HT parameters influence the achieved tem-
perature and thermal dose during HT.
Relationship between thermal dose parameters and
outcome in other tumor types
Relationships between thermal dose parameters and clinical
outcome have not only been found in recurrent breast can-
cer, but also in cervical carcinomas [21,22,64], sarcomas
[56,65], rectal cancer [66], brain tumors [67] and melanomas
[2,68]. Thermal dose variables (maximum CEM43, CEM43T50,
CEM43T90, CEM43T100, and TRISE) [2,21,22,56,64,65], min-
imum temperature variables (minimum temperature, T90)
[65,67,69] and maximum temperature variables [2] were
found to relate to outcome.
The first randomized controlled study showing a relation-
ship between thermal dose achieved during HT and outcome
was published in 1984 [70]. Dewhirst and Sim randomized
236 dogs and cats with a variety of cancers to either receive
RT alone or RTþHT. In the RTþHT group (n¼ 116) a rela-
tionship between CEM43T100 and both CR and duration of
LC was found, while the maximum CEM43 was related to
thermal injury. Animals achieving an average CEM43T100 1
during all HT treatments had a CR comparable to the group
treated with RT alone (n¼ 120). Furthermore, extensive tem-
perature data from animal studies indicated that the coolest
part of the tumor determined the response to RTþHT
[70–72]. Interestingly, in animals with tumors that showed
very heterogeneous heating more skin toxicity was found
while the response rate decreased [72,73]. It is likely that the
maximum temperature limited the HT operator to increase
the temperature in the coolest part of the tumor. These pio-
neering studies paved the way for subsequent human trials.
CEM43
The suitability of CEM43 to represent thermal dose is a
widely debated subject, as excellently summarized by van
Rhoon in 2016 [17]. CEM43 is based on the direct cytotoxic
effect of heat. The amount of cell death depends on the
Table 2. The location of temperature sensors (skin and/or invasively) used for
calculation of a thermal dose parameter influences the relationship of the par-
ameter with outcome.
Univariate relationship Multivariate relationship
Skin Invasive
Skinþ
invasive Skin Invasive
Skinþ
invasive
Complete response 0/0 6/19 2/7 0/0 1/6 0/0
Duration of local control 0/0 9/14 0/8 0/0 3/15 0/4
Overall survival 0/0 0/0 1/1 0/0 1/3 1/1
Thermal toxicity 2/2 2/10 4/8 4/4 1/1 0/4
The result is the number of significant relationships (p< .05) per thermal dose
category divided by the total number of reported relationships (significant
p< .05, trend .05< p< .1, or no relationship p .1).
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temperature and duration of heating and has been shown to
be suitable for predicting the risk of adverse events of
RTþHT in normal tissue [48,63]. CEM43 does not include all
underlying synergistic mechanisms of HT to RT when used to
predict treatment efficacy of combined RTþHT; for example,
inhibiting DNA damage repair [74], selective killing of radio-
resistant hypoxic tumor cells [75] and increased radiosensitiv-
ity by enhanced tissue perfusion and reoxygenation [76].
Each of these mechanisms display a different dose–effect
relationship [10]. Furthermore, instead of representing the
direct effect of HT quality, the measured CEM43T90 might
instead actually represent tumor characteristics (i.e., perfusion
level), which are predictive of sensitivity to RT. The ability to
realize a uniform and high temperature is likely to be associ-
ated with a homogeneously perfused and thus well-oxygen-
ated tumor. Such a tumor would generally respond well to
treatment, even with RT alone. Therefore, the development
of a new dose parameter incorporating the combined
RTþHT effect and/or employing thermoradiotherapy plan-
ning [77] might more accurately represent the synergistic
effect of RT and HT in the whole area treated with RTþHT.
Nevertheless, most underlying HT mechanisms display
increasing HT effectiveness with higher temperatures. This
might explain why multiple clinical studies included in this
review did find a relationship between CR and CEM43 or
other thermal dose parameters (Figure 4). Consequently,
CEM43T90 has been deployed in a prospective setting to
investigate whether patients with superficial tumors treated
with CEM43T90 1 or CEM43T90> 10 had different out-
come. Indeed, superficial tumors treated with a thermal dose
CEM43T90> 10 had considerably longer duration of LC than
patients with CEM43T90 1 [16]. So although the CEM43
concept has shortcomings, at present this parameter does
show a relationship with outcome in many studies.
Conclusion
This systematic review shows that higher temperature and
thermal dose during hyperthermia therapy significantly
improve clinical outcome; complete response, local control,
and overall survival; and increase thermal toxicity for patients
with recurrent breast cancer treated with radiotherapy and
hyperthermia therapy. A sufficiently high hyperthermia ther-
apy dose is required to achieve the radiosensitizing effect of
hyperthermia therapy. Thermal dose parameters derived
from the surface have a relationship with thermal toxicity,
whereas invasive thermal dose parameters have a relation-
ship with response, local control and overall survival as well
as with thermal toxicity. Achieving a clinically relevant effect
of hyperthermia therapy when added to radiotherapy for
patients with locoregional recurrent breast cancer in previ-
ously irradiated area, requires ensuring a high hyperther-
mia dose.
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